Showing 3541-3550 of 4764 results for "".
- Novartis: New Data Show Cosentyx Has Durable Response Across Psoriatic Diseasehttps://practicaldermatology.com/news/novartis-new-data-show-cosentyx-has-durable-response-across-psoriatic-disease/2460068/A new comprehensive analysis shows the long-term efficacy and safety of secukinumab in multiple manifestations of psoriatic disease, including moderate-to-severe plaque-type, nail and palmoplantar psoriasis, psoriatic arthritis and ankylosing spondylitis. Data are derived from key Phase 3, random
- Aclaris Therapeutics: Positive 6-Month Results from Phase 2 Open-Label Trial of Topical ATI-502 in Androgenetic Alopeciahttps://practicaldermatology.com/news/aclaris-therapeutics-positive-6-month-results-from-phase-2-open-label-trial-of-topical-ati-502-in-androgenetic-alopecia/2460067/Results from a Phase 2 open-label clinical trial of ATI-502 (AGA-201), an investigational topical Janus Kinase (JAK) 1/3 inhibitor are promising for patients with androgenetic alopecia (AGA). Aclaris Therapeutics announced the findings and says 12-month data should be available by year’s en
- Lilly: 5-Year Sustained Efficacy and Safety Results for Taltz in Plaque Psoriasis at WCDhttps://practicaldermatology.com/news/lilly-5-year-sustained-efficacy-and-safety-results-for-taltz-in-plaque-psoriasis-at-wcd/2460066/Patients with moderate- to severe plaque psoriasis who continued to receive Taltz® (ixekizumab) maintained high levels of skin clearance with no unexpected safety outcomes for up to five years of treatment, according to new data Eli Lilly and Company is presenting at the World Congress of Der
- Data Show 2-Year Complete Response with AbbVie's Skyrizi: WCDhttps://practicaldermatology.com/news/data-show-2-year-complete-response-with-abbvies-skyrizi-wcd/2460064/New results presented by AbbVie show that a significant number of patients treated with Skyrizi™ (risankizumab) experienced complete skin clearance at week 94. These two-year results (up to 104 weeks) from the Phase 3 IMMhance study, evaluating the efficacy and safety of SKYRIZI in adu
- Registration Open for Skin of Color Update Meetinghttps://practicaldermatology.com/news/registration-open-for-skin-of-color-update-meeting/2460060/The medical education event focused on the dermatologic treatment of skin of color has a new name. Skin of Color Update, previously the Skin of Color Seminar Series, provides dermatologists with evidence-based research and practical pearls in treating skin of color, including patients with multir
- BTL Taps Drew Barrymore as First Emsculpt Celebrity Ambassadorhttps://practicaldermatology.com/news/btl-taps-drew-barrymore-as-first-emscuplt-celebrity-ambassador/2460052/Drew Barrymore is Emsculpt's first celebrity ambassador. Through her partnership with Emsculpt, the actress and lifestyle mogul will share her treatment experience and results with media and on her social media channels. Ba
- Study:Colorescience’s EnviroScreen Technology Fights Sun Damage, Environmental Factorshttps://practicaldermatology.com/news/studycoloresciences-enviroscreen-technology-fights-sun-damage-environmental-factors/2460051/Colorescience’s Patented EnviroScreen Technology suppresses free radical formation and demonstrates superior performance when tested against comparable products, according to a study in The Journal of Co
- Kylie Jenner Introduces Kylie Skinhttps://practicaldermatology.com/news/kylie-jenner-introduces-kylie-skin/2460046/Kylie Jenner’s new skincare lime, Kylie Skin, came out in true Kardashian-Jenner style with an all-pink party that included a roller skating rink, her famous family plus other A-listers. And the new line – which launched with six products
- Positive 90-Day Results from CONFORM Study: Recros Medicahttps://practicaldermatology.com/news/positive-90-day-results-from-conform-study-recros-medica/2460042/Ninety-day results from the CONFORM study assessing the efficacy, safety, and patient satisfaction of the Rotational Fractional Resection (RFR) procedure for submental contouring are promising. RFR is a novel, proprietary alternative to traditional approaches to treat skin laxity developed by
- FDA Approves Sorilux for Adolescent Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-sorilux-for-adolescent-plaque-psoriasis/2460039/The FDA has approved Mayne Pharma Group Limited's Sorilux (calcipotriene) Foam, 0.005% in adolescents 12 years and older. The FDA approved Sorilux in 2010 based on evidence from two eight-week placebo controlled clinical trials in patients with mild to moderate plaque psoriasis of t